Pomalyst

Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myeloma
Bristol-Myers Squibb snags quick Empliciti combo nod in multiple myeloma
Fierce Pharma
Bristol-Myers Squibb
AbbVie
Empliciti
FDA
Multiple Myeloma
Celgene
Pomalyst
Flag link:
Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review
Bristol-Myers (BMY) sBLA for Empliciti Gets Priority Review
Yahoo/Zacks.com
Bristol-Myers Squibb
Empliciti
Celgene
Pomalyst
Multiple Myeloma
Flag link:
With Revlimid and Pomalyst price increases, could Celgene be next on Trump’s to-call list?
With Revlimid and Pomalyst price increases, could Celgene be next on Trump’s to-call list?
Fierce Pharma
Pfizer
Celgene
drug pricing
Donald Trump
Revlimid
Pomalyst
Flag link:
Looking to grow blockbuster Pomalyst franchise, Celgene declares a win for multiple myeloma triplet in pivotal PhIII
Looking to grow blockbuster Pomalyst franchise, Celgene declares a win for multiple myeloma triplet in pivotal PhIII
Endpoints
Celgene
Pomalyst
Multiple Myeloma
clinical trials
Flag link:
Celgene takes its most aggressive price hikes yet on Revlimid, Pomalyst: analyst
Celgene takes its most aggressive price hikes yet on Revlimid, Pomalyst: analyst
Fierce Pharma
Celgene
Revlimid
Pomalyst
drug pricing
Flag link:
5 Reasons Celgene Will Be a Top Biotech Stock for the Next Decade
5 Reasons Celgene Will Be a Top Biotech Stock for the Next Decade
Motley Fool
Celgene
Revlimid
Pomalyst
Abraxane
Otezla
Flag link:
Celgene's Fastest-Growing Drugs
Celgene's Fastest-Growing Drugs
Motley Fool
Celgene
Otezla
Pomalyst
Flag link:
What's Next For Celgene
What's Next For Celgene
Motley Fool
Celgene
JPMHC 2017
Otezla
ozanimod
Revlimid
Pomalyst
Flag link:
New Merck Study Shows Combos Will Drive Celgene Growth: RBC
New Merck Study Shows Combos Will Drive Celgene Growth: RBC
Barron's
Merck
Celgene
Pomalyst
Flag link:
The top 10 most expensive drugs of 2013
The top 10 most expensive drugs of 2013
Fierce Pharma
drug pricing
Soliris
Alexion
Naglazyme
Biomarin
Kalydeco
Vertex
Cinryze
Shire
Sprycel
Bristol-Myers Squibb
Pomalyst
Celgene
Xyrem
Jazz Pharmaceuticals
Erbitux
Merck KGaA
Revlimid
Questcor
Mallinckrodt
H.P. Acthar Gel
Flag link:
Analysis of FDA side-effect reports flags Sanofi, Celgene meds
Analysis of FDA side-effect reports flags Sanofi, Celgene meds
Fierce Pharma
Celegene
FDA
Sanofi
side effects
Pomalyst
Tecfidera
Biogen Idec
Aubagio
Flag link:
Celgene's New Multiple Myeloma Drug Is Beating Amgen
Celgene's New Multiple Myeloma Drug Is Beating Amgen
TheStreet.com
Celgene
Multiple Myeloma
Amgen
Kyprolis
Pomalyst
Flag link:
Celgene's Multiple Myeloma Powerhouse
Celgene's Multiple Myeloma Powerhouse
Motley Fool
Multiple Myeloma
Celgene
Thalomid
Revlimid
Pomalyst
Flag link:
Celgene at ASCO: Ho-Hum, Ho-Hum, and Hmmm
Celgene at ASCO: Ho-Hum, Ho-Hum, and Hmmm
Motley Fool
Celgene
ASCO
Pomalyst
Abraxane
Revlimid
Flag link:
Celgene's Rich Pipeline Offers Growth
Celgene's Rich Pipeline Offers Growth
Seeking Alpha
Celgene
Eli Lilly
Bristol-Myers Squibb
Roche
ONYX Pharmaceuticals
Pomalyst
Revlimid
Abraxane
Flag link:
Celgene And The Race To Cure Multiple Myeloma
Celgene And The Race To Cure Multiple Myeloma
Seeking Alpha
Celgene
Multiple Myeloma
Pomalyst
Flag link:
Celgene Gets OK to Sell Blood Cancer Drug
Celgene Gets OK to Sell Blood Cancer Drug
Minyanville
Celgene
Pomalyst
Multiple Myeloma
Flag link: